• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 10:01:52 AM ET
    $NTEC
    Major Pharmaceuticals
    Health Care
    Get the next $NTEC alert in real time by email
    SC 13G/A 1 tm216476d39_sc13ga.htm SCHEDULE 13G/A

     

    CUSIP No: M53644148

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT 

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Intec Pharma Ltd.

    (Name of Issuer)

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    M53644148

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨     Rule 13d-1(b)

    x    Rule 13d-1(c)

    ¨     Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No: M53644148

     

      (1) NAMES OF REPORTING PERSONS
     
        CVI Investments, Inc.
     
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
     
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Cayman Islands
         
    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
     
    BENEFICIALLY (6) SHARED VOTING POWER **
     
      95,000
    OWNED BY
     
    EACH (7) SOLE DISPOSITIVE POWER
     
    REPORTING 0
     
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
     
      95,000
       
      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        95,000
       
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        2.4%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: M53644148

     

      (1) NAMES OF REPORTING PERSONS
     
        Heights Capital Management, Inc.
         
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
         
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Delaware
         

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
     
    BENEFICIALLY (6) SHARED VOTING POWER **
     
    OWNED BY 95,000
       
         
    EACH (7) SOLE DISPOSITIVE POWER
     
    REPORTING 0  
         
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
     
      95,000
       

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        95,000
     
     
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        2.4%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: M53644148

     

    Item 1.

      

    (a) Name of Issuer
     
      Intec Pharma Ltd. (the “Company”)
     
    (b) Address of Issuer’s Principal Executive Offices
     
      12 Hartom St., Har Hotzvim, Jerusalem 9777512, Israel

     

    Item 2(a).   Name of Person Filing

     

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the ordinary shares of the Company, no par value (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).   Address of Principal Business Office or, if none, Residence

     

      The address of the principal business office of CVI Investments, Inc. is:
     
      P.O. Box 309GT
      Ugland House
      South Church Street
      George Town
      Grand Cayman
      KY1-1104
      Cayman Islands
     
      The address of the principal business office of Heights Capital Management, Inc. is:
     
      101 California Street, Suite 3250
      San Francisco, California 94111

      

    Item 2(c).   Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)   Title of Class of Securities

     

    Ordinary Shares, no par value

     

    Item 2(e)   CUSIP Number

     

    M53644148

      

     

     

     

    CUSIP No: M53644148

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
         
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”).

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 indicates there were 3,948,226 Shares outstanding as of November 5, 2020.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

     

     

     

    CUSIP No: M53644148

     

    Item 7.        Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

       

     

     

    CUSIP No: M53644148

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021

     

    CVI INVESTMENTS, INC. HEIGHTS CAPITAL MANAGEMENT, INC.
       
    By: Heights Capital Management, Inc. By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Name: Brian Sopinsky

    Attorney, a copy of which was previously filed

    Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

       

     

     

    CUSIP No: M53644148

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

    *Previously filed

       

     

     

    Get the next $NTEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTEC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intec Closes Merger with Decoy Biosystems

    NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company," and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ("Decoy") and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company's therapeutic focus. Indaptus is expected to begin trading on the Nasdaq Capital Market at the open of trading on August 4, 2021, under the ticker symbol "INDP" and a new CUSIP number (45339J 105). The previous ticker symbol was "NTEC" (NA

    8/3/21 7:46:00 PM ET
    $NTEC
    Major Pharmaceuticals
    Health Care

    Intec Announces Expected Closing Date of Decoy Merger

    JERUSALEM, Aug. 3, 2021 /PRNewswire/ -- Intec Parent, Inc. (NASDAQ:NTEC) ("Intec Parent" or the "Company"), today announced that the pending and previously announced reverse merger (the "Decoy Merger") with Decoy Biosystems, Inc. ("Decoy") is currently expected to close after market hours today, Tuesday, August 3, 2021, subject to satisfaction or waiver of all closing conditions. Immediately following the closing, the combined company will be renamed "Indaptus Therapeutics, Inc.", and is expected to begin trading on The Nasdaq Capital Market under the new ticker symbol "INDP" upon the commencement of trading on Wednesday, August 4, 2021. In connection with the Decoy Merger and the previously

    8/3/21 12:45:00 PM ET
    $NTEC
    Major Pharmaceuticals
    Health Care

    Intec Announces $30 Million Private Placement Ahead of Decoy Merger

    JERUSALEM, July 26, 2021 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec Israel" or the "Company"), today announced that its wholly-owned subsidiary, Intec Parent, Inc. ("Intec US"), entered into a securities purchase agreement with a single, healthcare-focused institutional investor to raise $30 million in a private placement. The private placement is being consummated to satisfy one of the closing conditions of the previously announced reverse merger with Decoy Biosystems, Inc. (the "Decoy Merger"). In connection with the Decoy Merger, Intec Israel plans to effect a 1-for-4 reverse share split of its outstanding ordinary shares for the purpose of meeting Nasdaq's initial listing re

    7/26/21 8:00:00 AM ET
    $NTEC
    Major Pharmaceuticals
    Health Care

    $NTEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Intec Pharma Ltd. (0001638381) (Subject)

    2/16/21 10:01:52 AM ET
    $NTEC
    Major Pharmaceuticals
    Health Care

    $NTEC
    SEC Filings

    View All

    SEC Form 15-12B filed by Intec Pharma Ltd.

    15-12B - Intec Pharma Ltd. (0001638381) (Filer)

    8/13/21 5:02:32 PM ET
    $NTEC
    Major Pharmaceuticals
    Health Care

    SEC Form 25-NSE filed by Intec Pharma Ltd.

    25-NSE - Intec Pharma Ltd. (0001638381) (Subject)

    8/3/21 4:59:29 PM ET
    $NTEC
    Major Pharmaceuticals
    Health Care

    SEC Form 425 filed by Intec Pharma Ltd.

    425 - Intec Pharma Ltd. (0001638381) (Subject)

    7/23/21 4:35:31 PM ET
    $NTEC
    Major Pharmaceuticals
    Health Care